Form 4: Zimmer Biomet Director Kurdikar Acquires Phantom Stock Units

Director Devdatt Kurdikar reports acquisition of phantom stock units in Zimmer Biomet Holdings, Inc. under the Deferred Compensation Plan for Non-Employee Directors.

Summary

• On March 31, 2025, Devdatt Kurdikar, a director of Zimmer Biomet Holdings, Inc., acquired phantom stock units under the company's Deferred Compensation Plan for Non-Employee Directors.
• The transaction involved the accrual of 122.211 phantom stock units at a price of $112.51 per unit.
• Following the transaction, Kurdikar beneficially owns 507.728 phantom stock units.
• These units will be settled in shares of Zimmer Biomet common stock within sixty days after Kurdikar ceases to be a director.
• The report also includes 0.556 phantom stock units accrued on January 31, 2025, under the dividend reinvestment provision of the same plan.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. It reflects standard compensation practices.

Positives

• The acquisition of phantom stock units by a director signals confidence in the company's future performance.

Future Outlook

The phantom stock units will be settled in shares of Zimmer Biomet common stock within sixty days after Kurdikar ceases to be a director.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It reflects part of the compensation structure for non-employee directors.

Comparison to Industry Standards

• Deferred compensation plans are a common practice among publicly traded companies to attract and retain directors.
• The specifics of Zimmer Biomet's plan, such as the vesting schedule and settlement terms, would need to be compared to those of peer companies like Stryker, Johnson & Johnson (DePuy Synthes), and Medtronic to assess its competitiveness.
• The amount of phantom stock units granted can be benchmarked against similar grants to directors in comparable companies to determine if it is within the typical range.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term performance.

Key Dates

Keywords

Zimmer Biomet, Director, Phantom Stock Units, Deferred Compensation Plan, Beneficial Ownership, Form 4